
What is claimed is:

1. A use of a pharmaceutical composition comprising a benzenesulfonamide derivative and a pharmaceutically acceptable excipient thereof in the manufacture of a medicament for treating a malignant pleural effusion (MPE) in a subject in need thereof.

2. The use according to claim 1, wherein the benzenesulfonamide derivative is a compound represented by formula (I):



(I),

wherein R_1 to R_6 are each independently selected from the group consisting of H, C1-C6 linear or branched alkyl, C1-C6 linear or branched alkoxy, amino, halo, halo-substituted C1-C6 linear or branched alkyl, and sulfonamide group.

3. The use according to claim 2, wherein the compound of formula (I) is selected from the group consisting of *p*-toluenesulfonamide, *o*-toluenesulfonamide, N-ethyl-*p*-toluene sulfonamide, N-ethyl-*o*-toluene sulfonamide, N-cyclohexyl-*p*-toluene sulfonamide and a combination thereof.

4. The use according to claim 1, wherein the pharmaceutically acceptable excipient is selected from the group consisting of a filler, a binder, a preservative, a disintegrating agent, a lubricant, a suspending agent, a wetting agent, a solvent, a surfactant, an acid, a flavoring agent, polyethylene glycol (PEG), alkylene glycol, sebacic acid, dimethyl sulfoxide, alcohol and a combination thereof.

5. The use according to claim 1, wherein the benzenesulfonamide derivative is present in an amount ranging from about 10% to about 50% by weight.

6. The use according to claim 5, wherein the pharmaceutical composition comprises 20% to 40% by weight of the benzenesulfonamide derivative.

7. The use according to claim 5, wherein the pharmaceutical composition further comprises at least one of 10%-40% by weight of PEG-400, 5%-10% by weight of 1,2-propylene glycol, 1%-5% by weight of sebacic acid, 10%-20% by weight of 2-ethyl-1,3-hexanediol, 0%-10% by weight of dimethyl sulfoxide and 0%-10% by weight of ethanol.

8. The use according to claim 1, wherein the pharmaceutical composition is in a form selected from the group consisting of an injection formulation, dry powder, a tablet, oral liquid, a wafer, a film, a lozenge, a capsule, granule, and a pill.

9. The use according to claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is to be administered to the subject in a therapeutically effective amount of from about 825 mg to about 6600 mg per day.

10. The use according to claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is to be administered to the subject in a therapeutically effective amount of from about 990 mg to about 2640 mg per day.

11. The use according to claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical

composition is to be administered to the subject in a therapeutically effective amount of from about 1000 mg to about 1800 mg per day.

12. The use according to claim 1, wherein the therapeutically effective amount of the benzenesulfonamide derivative to be administered to the subject during the treatment is in a range of from about 2475 mg to about 27000 mg.

13. The use according to claim 1, wherein the pharmaceutical composition is to be administered to the subject intratumorally, intravenously, subcutaneously, intradermally, orally, intrathecally, intraperitoneally, intranasally, intramuscularly, intrapleuraly, or through nebulization.

14. The use according to claim 1, wherein the subject is suffering from cancer.

15. The use according to claim 14, wherein the cancer is at least one selected from the group consisting of lung cancer, breast cancer, lymphoma, leukemia, and mesothelioma.

16. The use according to claim 1, wherein the subject is to be administered at least one additional malignant pleural effusion (MPE) therapy to the subject.

17. The use according to claim 16, wherein the additional MPE therapy is chest drainage, video-assisted thoracic surgery (VATS), intrathoracic administration, pleural fixation, whole body chemotherapy, radiotherapy, or thermal therapy.